Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

Corporate Breaking News

Home : Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

Sep 12 2019	Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
GOTHENBURG, Sweden, Sept. 12, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study (ISO-CC-007) in metastatic colorectal cancer...


Source:https://www.prnewswire.com:443/news-releases/isofol-announces-that-an-abstract-has-been-accepted-for-presentation-at-the-2019-esmo-congress-300916756.html

Related News
» Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001 » Strekin AG verkündet den Abschluss der Patientenrekrutierung der RESTORE Phase 3 klinischen Studie mit STR001